Invivyd was invited to participate in an FDA-EMA workshop on SARS-CoV-2 monoclonal antibodies held on December 15, 2022. Invivyd’s chief scientific officer, Laura Walker, Ph.D., alongside Eli Lilly and Company and Regeneron Pharmaceuticals, Inc., presented a joint industry approach for anti-spike monoclonal antibody development to keep pace with SARS-CoV-2 variants. The meeting featured presentations by scientists, clinicians, regulators, and industry representatives to discuss alternative strategies to support the expedited availability of novel monoclonal antibody therapies including those based on development stage products that have reported positive safety and efficacy data in clinical trials. The industry presentation highlighted the significant unmet medical need for therapeutic options to prevent and treat COVID-19 along with scientifically sound, data driven policy change recommendations to shorten development timelines and keep pace with the rapid evolution of variants.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on IVVD:
- Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA Workshop
- Invivyd appoints Gowler as COO and commercial Officer, Pete Schmidt MD to CMO
- Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer
- Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19
- Invivyd reports Q3 EPS (42c), consensus (49c)
